KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Charles River Laboratories International (CRL) over the last 16 years, with Q3 2025 value amounting to $54.4 million.

  • Charles River Laboratories International's Net Income towards Common Stockholders fell 2075.89% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.5 million, marking a year-over-year decrease of 12020.96%. This contributed to the annual value of $10.3 million for FY2024, which is 9783.05% down from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's Net Income towards Common Stockholders is $54.4 million, which was down 2075.89% from $52.3 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's Net Income towards Common Stockholders peaked at $189.1 million during Q4 2022, and registered a low of -$215.7 million during Q4 2024.
  • In the last 5 years, Charles River Laboratories International's Net Income towards Common Stockholders had a median value of $90.0 million in 2024 and averaged $79.4 million.
  • As far as peak fluctuations go, Charles River Laboratories International's Net Income towards Common Stockholders soared by 4894.19% in 2022, and later crashed by 21529.53% in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's Net Income towards Common Stockholders stood at $139.8 million in 2021, then surged by 35.24% to $189.1 million in 2022, then fell by 1.07% to $187.1 million in 2023, then tumbled by 215.3% to -$215.7 million in 2024, then surged by 125.23% to $54.4 million in 2025.
  • Its Net Income towards Common Stockholders was $54.4 million in Q3 2025, compared to $52.3 million in Q2 2025 and $25.5 million in Q1 2025.